Symptomatic SARS-CoV-2 breakthrough infections broaden the repertoire of Spike-reactive CD4 T cells
Year: 2025
Type: article
Language: en
Topic: SARS-CoV-2 and COVID-19 Research
Authors and affiliations:
raw_author_name: Emil Johansson
raw_affiliation_strings: Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI)
Department of Experimental Medical Science, Lund University
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, California, USA
Department of Experimental Medical Science, Lund University, Lund, Sweden
raw_author_name: Yeji Lee
raw_affiliation_strings: Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI)
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, California, USA
raw_author_name: Vicente Fajardo-Rosas
raw_affiliation_strings: Bioinformatics and Systems Biology Graduate Program, University of California, San Diego (UCSD)
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI)
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, California, USA
Bioinformatics and Systems Biology Graduate Program, University of California, San Diego (UCSD), La Jolla, California, USA
raw_author_name: Adam Abawi
raw_affiliation_strings: Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI)
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, California, USA
raw_author_name: Ashmitaa Logandha Ramamoorthy Premlal
raw_affiliation_strings: Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI)
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, California, USA
raw_author_name: April Frazier
raw_affiliation_strings: Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI)
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, California, USA
raw_author_name: Jason A. Greenbaum
raw_affiliation_strings: Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI)
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, California, USA
raw_author_name: Pandurangan Vijayanand
raw_affiliation_strings: Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI)
Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD)
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, California, USA
Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, California, USA
raw_author_name: Ricardo da Silva Antunes
raw_affiliation_strings: Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI)
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, California, USA
raw_author_name: Alessandro Sette
raw_affiliation_strings: Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI)
Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD)
Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, California, USA
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, California, USA